Daehan New Pharm Co. Ltd (054670) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.034x

Based on the latest financial reports, Daehan New Pharm Co. Ltd (054670) has a cash flow conversion efficiency ratio of 0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.43 Billion ≈ $3.00 Million USD) by net assets (₩129.44 Billion ≈ $87.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 054670 net asset quality score to measure how much of total assets are equity-financed.

Daehan New Pharm Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Daehan New Pharm Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Daehan New Pharm Co. Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.

Daehan New Pharm Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Daehan New Pharm Co. Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Beyaz Filo Oto Kiralama AS IS:BEYAZ	-0.268x
Boom Logistics Ltd AU:BOL	0.104x
Immutep Limited F:YP1A	-0.119x
Elicio Therapeutics Inc. NASDAQ:ELTX	8.104x
Chang Type Industrial Co Ltd TW:1541	0.021x
Kamat Hotels (I) Limited NSE:KAMATHOTEL	0.085x
XTPL SA WAR:XTP	-0.187x
Prinsiri Public Company Limited BK:PRIN	0.019x

Annual Cash Flow Conversion Efficiency for Daehan New Pharm Co. Ltd (2014–2024)

The table below shows the annual cash flow conversion efficiency of Daehan New Pharm Co. Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see 054670 market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩125.44 Billion ≈ $85.01 Million	₩18.95 Billion ≈ $12.84 Million	0.151x	+31.44%
2023-12-31	₩109.36 Billion ≈ $74.11 Million	₩12.57 Billion ≈ $8.52 Million	0.115x	-16.99%
2022-12-31	₩102.96 Billion ≈ $69.77 Million	₩14.25 Billion ≈ $9.66 Million	0.138x	-31.16%
2021-12-31	₩82.47 Billion ≈ $55.89 Million	₩16.58 Billion ≈ $11.24 Million	0.201x	-15.19%
2020-12-31	₩57.13 Billion ≈ $38.72 Million	₩13.55 Billion ≈ $9.18 Million	0.237x	-36.75%
2019-12-31	₩61.07 Billion ≈ $41.38 Million	₩22.89 Billion ≈ $15.51 Million	0.375x	-21.12%
2018-12-31	₩43.08 Billion ≈ $29.19 Million	₩20.47 Billion ≈ $13.87 Million	0.475x	+1113.94%
2017-12-31	₩51.72 Billion ≈ $35.05 Million	₩-2.42 Billion ≈ $-1.64 Million	-0.047x	-138.14%
2016-12-31	₩71.20 Billion ≈ $48.25 Million	₩8.75 Billion ≈ $5.93 Million	0.123x	+21.58%
2015-12-31	₩77.20 Billion ≈ $52.32 Million	₩7.80 Billion ≈ $5.29 Million	0.101x	-25.43%
2014-12-31	₩73.89 Billion ≈ $50.07 Million	₩10.02 Billion ≈ $6.79 Million	0.136x	--

About Daehan New Pharm Co. Ltd

KQ:054670 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$53.26 Million

₩78.60 Billion KRW

Market Cap Rank

#21578 Global

#1248 in Korea

Share Price

₩5600.00

Change (1 day)

+3.90%

52-Week Range

₩5090.00 - ₩7510.00

All Time High

₩21012.38